TrialHaematologica2018

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.

Jesús F San-Miguel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.